Evidence map›Paper›PMID 32250288›Full record

ArticleCancer biomarkers : section A of Disease markers2020

Molecular characterisation in tongue squamous cell carcinoma reveals key variants potentially linked to clinical outcomes.

Abeer A Alsofyani, Ashraf Dallol, Suha A Farraj, Rawiah A Alsiary, Alaa Samkari, Baraa T Alhaj-Hussain, Jalaluddin Azam Khan, Jaudah Al-Maghrabi, Shadi S Al-Khayyat, Heba Alkhatabi and 6 more

Abstract read
In one paragraph

Article in Cancer biomarkers : section A of Disease markers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Abeer A AlsofyaniKing Abdullah International Medical Research Center and King Saudbin Abdulaziz University for Health Sciences, King Abdulaziz Medical City, National Guard Health Affairs, Jeddah, Saudi Arabia.
Ashraf DallolCenter of Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, Saudi Arabia.
Suha A FarrajSpecial Infectious Agent Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.
Rawiah A AlsiaryKing Abdullah International Medical Research Center and King Saudbin Abdulaziz University for Health Sciences, King Abdulaziz Medical City, National Guard Health Affairs, Jeddah, Saudi Arabia.
Alaa SamkariDepartment of Pathology and Laboratory Medicine, King Abdulaziz Medical City, National Guard Health Affairs, Jeddah, Saudi Arabia.
Baraa T Alhaj-HussainDepartment of Pathology and Laboratory Medicine, King Abdulaziz Medical City, National Guard Health Affairs, Jeddah, Saudi Arabia.
Jalaluddin Azam KhanDepartment of Biochemistry, Faculty of Science, King Abdulaziz University, Jeddah, Saudi Arabia.
Jaudah Al-MaghrabiDepartment of Pathology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
Shadi S Al-KhayyatFaculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
Heba AlkhatabiCenter of Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, Saudi Arabia.
Aisha ElaimiCenter of Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, Saudi Arabia.
Abdelbaset BuhmeidaCenter of Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, Saudi Arabia.
Ayman Khalid JohargyMedical Microbiology Department, Faculty of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia.
Adel M AbuzenadahCenter of Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, Saudi Arabia.
Esam I AzharDepartment of Medical Laboratory Technology, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia.
Mohammed H Al-QahtaniCenter of Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOral tongue squamous cell carcinoma (OTSCC) is a highly aggressive malignancy characterized by frequent recurrence, poor survival with relatively few therapeutic options due to the late diagnosis in many cases.

objectivesUnderstanding the molecular pathways underlying OTSCC tumourigenesis and the discovery of diagnostic and/or prognostic biomarkers.

methodsWe performed high-throughput mutational analysis of 44 OTSCC formalin-fixed paraffin-embedded (FFPE) cases using the Cancer Hotspots Panel (CHP) v2 on the Ion Torrent™platform. We determined the frequency of human papilloma virus (HPV) using PCR and Epstein bar virus (EBV) positivity using immunohistochemistry. As a control for EBV infection we screened matched non-tumourous tissues.

resultsSequencing analysis identified missense, nonsense and frameshift mutations in TP53 (66%), PIK3CA (27%), CDKN2A (25%), EGFR (18%), and PTEN (14%). Interestingly, no significant associations were found between damaging mutations and clinicopathological data. A total of 10/44 of the OTSCC samples (23%) tested was positive for HPV18 DNA. OTSCC patients with positive HPV infection had worse overall survival compared to HPV-negative cases as determined by Kaplan-Meier survival (p= 0.023). Furthermore, EBNA1 expression showed a strong tumour-enriched expression pattern in 20 out of 21 samples (95%) in the epithelial compartments of the tissues analysed.

conclusionsTaken together, this study highlights that the two most common events in OTSCC are TP53 mutations and EBV positivity. Helping to understand the contribution of TP53 mutations and EBV infection events could serve as useful biomarkers for OTSCC.

Indexed as

AdultAgedAged, 80 and overAge FactorsBiomarkers, TumorCarcinogenesisCell Line, TumorDNA Mutational AnalysisDNA, ViralFemaleHuman papillomavirus 18HumansImmunohistochemistryKaplan-Meier EstimateMaleMiddle AgedBiomarkers, TumorDNA, ViralTP53 protein, humanTumor Suppressor Protein p53biomarkersEBVHPVoral cancerTongue cancer

Identifiers

PMID32250288
PMCPMC12662348

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.